The analysis included demographic (age, sex), pre‐treatment (reported at qualification: oral glucocorticosteroids use, total IgE serum level, peripheral blood eosinophilia, co‐morbidities: atopic dermatitis, chronic allergic rhinitis or sinusitis) and treatment‐related data (treatment time, current treatment status, reason for early termination of therapy, year of discontinuation, rediagnostics, requalification). This evidence concerns the gene IGHE and Increased total eosinophil count.